eligibility_summary
Adults ≥18 with DLBCL (incl. transformed) and TP53 del/mut, 1–3 prior lines and relapsed/refractory, measurable PET+ lesions, adequate counts/liver/renal, ECOG <=2, life expectancy >3 mo, contraception. Exclude: prior selinexor/XPO1, anti-DLBCL <21d, surgery <14d, auto-HSCT <100d, allo-HSCT <180d or active GVHD, CAR-T <90d, neuropathy >=grade 2, serious illness/uncontrolled infection, active HBV/HCV/HIV, malabsorption, pregnancy/lactation, no consent, low weight, live vaccine <28d.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Single-arm Phase II in TP53-altered relapsed/refractory DLBCL testing SR-GDP: selinexor plus R-GDP (rituximab, gemcitabine, cisplatin, dexamethasone), with selinexor maintenance for responders. Drug types/mechanisms: Selinexor (oral SINE, XPO1/CRM1 inhibitor) blocks nuclear export, retaining tumor-suppressors (p53/p73/FOXO) and IκB, suppressing NF-κB and inducing apoptosis despite TP53 alterations. Rituximab (anti-CD20 IgG1 mAb) depletes malignant B cells via ADCC/CDC and apoptosis. Gemcitabine (antimetabolite) inhibits DNA synthesis, cisplatin (platinum) crosslinks DNA, dexamethasone (glucocorticoid) is lymphocytotoxic/anti-inflammatory. Targets: CD20+ B-cell lymphoma cells, XPO1-mediated nuclear export, TP53/NF-κB pathways, DNA replication/repair, apoptotic pathways.